As a result, PADI4 inhibition has been studied extensively as an approach to alleviate NET-associated pathologies that manifest in diabetes, sepsis, infection-induced lung injury, age-related cardiac fibrosis, deep-vein thrombosis and myocardial ischemia [137–142]. Here, PADI4 is linked to Sepsis.